Mirvetuximab Soravtansine Exposure and Incidence of Cataract Surgery
This cohort study evaluates the incidence of cataract surgery among patients receiving mirvetuximab soravtansine to treat ovarian cancer.
Authors
- Jordyn Silverstein (ORCID: https://orcid.org/0000-0002-8573-7145)
- Dennis J. Slamon (ORCID: https://orcid.org/0000-0002-6330-498X)
- Edmund Yik Kong Tsui (ORCID: https://orcid.org/0000-0001-7532-9191)
- Oladunni Alomaja
- Chi‐Hong Tseng (ORCID: https://orcid.org/0000-0002-2549-6167)
- Bridget Johnson (ORCID: https://orcid.org/0000-0002-6070-0207)
- Dana M. Chase
- Gottfried E. Konecny
- Alexandra Smick
- Ritu Salani
Institutions
- University of California, Los Angeles (US)
- University of California System (US)
- Doheny Eye Institute (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2026-05-21
- DOI
- https://doi.org/10.1001/jamanetworkopen.2026.14557
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00